Scientific committees advising the EU have repeatedly concluded that oestradiol-17β must be considered a 'complete carcinogen ...

Dr Avan Armaghani discusses earlier use of ADCs, artificial intelligence for recurrence prediction, and new endocrine therapy ...

Two post-doctoral fellowships, two project grants, and one PhD scholarship have today been announced as part of the Cancer ...

In an effort to save costs, the National Institute of Excellence in Health and Social Services (INESSS) published a ...

This guide provides an informative and educational overview of stage 3 papillary thyroid cancer (PTC) to help drive a ...

Over the past four decades, death rates for most cancers have declined. Uterine cancer is an exception. Now the fourth most ...

The MHRA has approved inavolisib for adults with PIK3CA-mutated HR+/HER2– breast cancer, offering a new targeted first-line ...

Here’s what science actually shows about declining testosterone in young adults, and why treatment is rarely the first answer ...

Novartis Canada is deeply disappointed by the recent Institut national d'excellence en santé et en services sociaux (INESSS) ...

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical data for ATNM-400, a first-in-class ...

The UK MHRA has granted approval to Roche Products’ inavolisib to treat adults diagnosed with HR-positive, HER2-negative ...

A landmark review published today in Genomic Psychiatry challenges researchers to fundamentally reconsider how the field ...